This summary was created by AI, based on 22 opinions in the last 12 months.
Experts are generally positive on Merck & Company, highlighting the company's strong pipeline, particularly in oncology, and its ability to replace sales from drugs going off-patent. The company's key drug, Keytruda, has been a major driver of sales, but the upcoming patent expirations pose a challenge. However, the recent acquisition of Prometheus Biosciences is seen as a strategic move to diversify the company's portfolio. Overall, there is optimism about Merck's future performance and potential for growth.
Shares jumped today after getting approval for their pulmonary hypertension drug. This is huge. In 2023, 40% of their sales were from the keytruda drug, but this will go off patent in 2028
Absolutely a reasonable choice in the sector. Beat numbers last quarter. Lots of cash, ability to buy assets in areas of growth or where they want to add expertise. Increased guidance. Worth owning.
Better pipeline than PFE. Very strong oncology drug, proving effective in cocktail form against different cancers. This one drug represents over 40% of revenues. Patent on this one runs off around 2027-28, but pipeline is robust.
He owns ELI and AZN instead. MRK's key drug, Keytruda, is an anti-cancer treatment which drove their sales up 21% last year, and amounts to nearly 30% for their sales, but the patent cliff will happen in 2028. So, MRK must replace those sales (drug pipeline or buy a company). Be cautious here.
Portfolio of cancer-fighting stars. Great portfolio and great pipeline. Low valuation of 12x earnings. AAA balance sheet, good future. Good times ahead. Yield is 3%.
(Analysts’ price target is $124.26)A cheap stock. Their Keytruda drug did very well, perhaps the best-selling drug of all time.
Upgraded today and he agrees. His #1 healthcare pick this year. A key drug will come off patent in 2028, but they have tons of drugs to replace it. They beat and bottom lines.
Healthcare is having a poor year, but they have a tremendous drug pipeline and strong balance sheet.
Had great success during the pandemic; their vaccine led. The company just offered growth warnings. He prefers Merck for its better valuation and their key drug Keytruda which makes up 35% of their revenue.
Benefitted from Covid vaccines. Patent expirations in a couple of years. How will they continue to grow? Company is confident in acquisitions and internal R&D. She's looking at it, no decision yet. Cheap multiple, attractive yield. More of a deep value play.
MRK's done relatively better. Drugs going off patent also, but pipeline is a bit better. She's looking at this one too, still assessing.
She's overweight the healthcare sector as a whole, to withstand both volatility and a potential recession. Diverse portfolio. Earnings have climbed for years. Gained over 20% in August alone, so could be start of an uptrend. Better-than-expected earnings and sales. Increased guidance. Yield is 2.65%.
(Analysts’ price target is $123.11)His homework shows that MRK is an excellent opportunity on pipeline, future growth, earnings, and cashflow.
Can do the heavy lifting in your portfolio.
Merck & Company is a American stock, trading under the symbol MRK-N on the New York Stock Exchange (MRK). It is usually referred to as NYSE:MRK or MRK-N
In the last year, 17 stock analysts published opinions about MRK-N. 13 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Merck & Company.
Merck & Company was recommended as a Top Pick by on . Read the latest stock experts ratings for Merck & Company.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
17 stock analysts on Stockchase covered Merck & Company In the last year. It is a trending stock that is worth watching.
On 2024-04-25, Merck & Company (MRK-N) stock closed at a price of $130.43.
It reports Thursday. He expects them to announce new drug applications, the anti-cancer portfolio and their acquisitions.